Mr. Peter Whitehead reports

LIGHT AI ANNOUNCES PARTNERSHIP WITH ELIQUENT LIFE SCIENCES TO SUPPORT BRINGING ITS CUTTING-EDGE AI MEDICAL TECHNOLOGIES TO THE U.S. MARKET

Light AI Inc. has entered its partnership with Eliquent Life Sciences, a leading regulatory, quality and safety consulting firm for the life science industry. This collaboration aims to help Light AI navigate the complexities of the Food and Drug Administration regulatory pathway and to ensure Light AI's innovative medical solutions meet all necessary premarket submission requirements.

Eliquent will partner with the company to provide comprehensive support in designing a robust U.S. Food and Drug Administration regulatory strategy, leveraging its deep industry knowledge and extensive experience to facilitate efficient interactions with the FDA. This partnership marks a significant milestone in Light AI's journey to bring cutting-edge medical technologies to the U.S. market.

Eliquent Life Sciences delivers integrated solutions that support pharmaceutical, biotechnology, medical device and combination product companies across the product life cycle. Eliquent's full-service platform supports innovators across therapeutic modalities, phase-based pathways and major global markets. The firm's unprecedented assembly of regulatory leaders, industry experts and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards.

"We are thrilled to partner with Eliquent," said Peter Whitehead, chief executive officer of Light AI. "Their expertise in FDA regulatory strategy is unparalleled, and their support will be invaluable as we develop a clear and effective pathway for our device submissions. This collaboration will help us ensure that our solutions meet the highest standards of safety and efficacy. Eliquent's proven track record in guiding companies through the regulatory landscape will be instrumental in Light AI's efforts to achieve timely FDA marketing authorization and ultimately improve patient care through innovative technology."

"Eliquent looks forward to working with the Light AI team as they seek U.S. FDA marketing authorization for their innovative technology," said Daniel Schultz, principal of medical devices and combination products at Eliquent.

About Light AI Inc.

Light AI is a health care company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: It applies artificial intelligence algorithms to smart phone images -- starting with images of StrepA -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind: Its hardware platform is the 4.5 billion smart phones that exist in the world today.

In pre-Food and Drug Administration validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus. The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease, which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.